DE69620661T2 - 2-Phenyl-3-Azoylbenzothiophene zur Verminderung des Serumkalziumspiegels - Google Patents

2-Phenyl-3-Azoylbenzothiophene zur Verminderung des Serumkalziumspiegels

Info

Publication number
DE69620661T2
DE69620661T2 DE69620661T DE69620661T DE69620661T2 DE 69620661 T2 DE69620661 T2 DE 69620661T2 DE 69620661 T DE69620661 T DE 69620661T DE 69620661 T DE69620661 T DE 69620661T DE 69620661 T2 DE69620661 T2 DE 69620661T2
Authority
DE
Germany
Prior art keywords
phenyl
serum calcium
azoylbenzothiophenes
reduce
calcium level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620661T
Other languages
English (en)
Other versions
DE69620661D1 (de
Inventor
Susan M Boss
Willard H Dere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69620661D1 publication Critical patent/DE69620661D1/de
Application granted granted Critical
Publication of DE69620661T2 publication Critical patent/DE69620661T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrrole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69620661T 1995-01-30 1996-01-29 2-Phenyl-3-Azoylbenzothiophene zur Verminderung des Serumkalziumspiegels Expired - Fee Related DE69620661T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/380,881 US5512583A (en) 1995-01-30 1995-01-30 Methods of decreasing serum calcium levels

Publications (2)

Publication Number Publication Date
DE69620661D1 DE69620661D1 (de) 2002-05-23
DE69620661T2 true DE69620661T2 (de) 2002-11-14

Family

ID=23502813

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620661T Expired - Fee Related DE69620661T2 (de) 1995-01-30 1996-01-29 2-Phenyl-3-Azoylbenzothiophene zur Verminderung des Serumkalziumspiegels

Country Status (19)

Country Link
US (1) US5512583A (de)
EP (1) EP0723780B1 (de)
JP (1) JPH10513184A (de)
KR (1) KR19980701731A (de)
CN (1) CN1086943C (de)
AT (1) ATE216232T1 (de)
AU (1) AU701262B2 (de)
CA (1) CA2211530A1 (de)
CZ (1) CZ286161B6 (de)
DE (1) DE69620661T2 (de)
DK (1) DK0723780T3 (de)
ES (1) ES2172633T3 (de)
HU (1) HUP9801335A3 (de)
NO (1) NO973470D0 (de)
NZ (1) NZ302546A (de)
PT (1) PT723780E (de)
RU (1) RU2176503C2 (de)
UA (1) UA43389C2 (de)
WO (1) WO1996023501A1 (de)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4320896A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss

Also Published As

Publication number Publication date
AU701262B2 (en) 1999-01-21
UA43389C2 (uk) 2001-12-17
CZ286161B6 (cs) 2000-01-12
PT723780E (pt) 2002-08-30
EP0723780A3 (de) 1996-09-11
HUP9801335A3 (en) 2000-03-28
ES2172633T3 (es) 2002-10-01
RU2176503C2 (ru) 2001-12-10
MX9705697A (es) 1997-10-31
NZ302546A (en) 2000-06-23
EP0723780B1 (de) 2002-04-17
CN1086943C (zh) 2002-07-03
DK0723780T3 (da) 2002-06-17
CZ240397A3 (cs) 1998-01-14
HUP9801335A2 (hu) 1999-05-28
WO1996023501A1 (en) 1996-08-08
KR19980701731A (ko) 1998-06-25
AU4862296A (en) 1996-08-21
DE69620661D1 (de) 2002-05-23
CA2211530A1 (en) 1996-08-08
JPH10513184A (ja) 1998-12-15
CN1172432A (zh) 1998-02-04
EP0723780A2 (de) 1996-07-31
US5512583A (en) 1996-04-30
NO973470L (no) 1997-07-28
NO973470D0 (no) 1997-07-28
ATE216232T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE233559T1 (de) Verwendung von benzothiophene zur behandlung von hypercholesterolämie
PL371046A1 (en) Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
ATE88891T1 (de) Verfahren zur verbesserung des gedaechnisses oder zur beseitigung des gedaechnis-mangels mit arylamido-(und arylthioamido)-azabicycloalkanen.
AU8155994A (en) Methods of inhibiting the symptoms of premenstrual syndrome/ late luteal phase dysphoric disorder
ZA948024B (en) Methods for the treatment of peri-menopausal syndrome
DE69128516D1 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
DE69402173D1 (de) Hemmung von Thrombin
DK0848004T3 (da) Pyrrolidinderivater med inhiberende aktivitet mod phospholipase A2
DE69625696T2 (de) Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
ATE203404T1 (de) Methode zur hemmung der endometriose
NZ220546A (en) Benzothiophene- and benzofuran- amides and compositions
NO963370L (no) Nye mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[cÅazepin-3-on-disulfidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
PT651999E (pt) Metodos de inibicao da fibrose uterina
DE69412049T2 (de) Hemmung von dysfunctionalen Uterusblutungen
ES2162844T3 (es) Inhibicion de la disgenesia de ovarios, pubertad tardia o infantilismo sexual.
DE69620661T2 (de) 2-Phenyl-3-Azoylbenzothiophene zur Verminderung des Serumkalziumspiegels
ATE205742T1 (de) Zeolitische entschwefelungsmittel und ihre verwendung zur behandlung von c02 enthaltenden gasen
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
DE58902320D1 (de) Thienyl-piperazinone, ihre herstellung und verwendung.
ES2162062T3 (es) Estabilizacion de nitrilos.
MX9709542A (es) Modulacion de los canales de calcio.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee